Under one in 10 individuals that would benefit from weight-loss injections such as Wegovy can access them, states the global health agency as it publishes its inaugural recommendations on the therapies.
With in excess of 1,000,000,000 people worldwide now classified as obese, it is urging more widespread and fairer availability to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"The latest guidelines acknowledges that obesity is a chronic disease that can be treated with holistic and continuous treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are key barriers to widespread access to the injections that can aid individuals in losing considerable weight, says the agency.
Skinny Jab Supply Crisis
Despite the present most optimistic scenario, the manufacturing of these medications could only cover around 100 million people – under 10% of those who need them, according to the health organization.
The guideline calls on governments and firms to expand availability, through measures such as voluntary licensing.
The intellectual property rights on the active ingredient – the main component of the drug Wegovy – is due to expire in several countries in 2026.
The Way Obesity Injections Function
These medications mimick a biological compound to reduce digestion speed, suppress the appetite and increase satiety so individuals eat less.
Patients typically start to lose weight within a few weeks of beginning the regular doses.
Research indicates patients may regain a significant portion after a year of stopping the drug, as their typical appetite come back.
To be overweight or obese elevates your chance for developing diseases, such as diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight concerns individuals in all nations and was associated with millions of deaths worldwide in 2024, as per the health agency.
